Diabetic macular oedema (DME) is a late microvascular complication of diabetes mellitus and a leading cause of vision loss in working-age adults worldwide, yet a substantial proportion of patients show incomplete response to current anti-VEGF therapies and require frequent injections. To address this gap, a study evaluated the effectiveness of faricimab, an inhibitor of both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2) pathways, using a treat-and-extend regimen, including both treatment-naïve patients and those switched from other anti-VEGF treatments, involving 184 eyes with DME.
The study found that visual acuity improved significantly in treatment-naïve eyes, increasing from 69.7±15 to 73.9±14.1 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters at 12 months, while remaining stable in pretreated eyes (71.2±14.2 vs 73.0±12.9). Central subfield…
